Randomized double-blind controlled trial of roflumilast at acute exacerbations of
|
|
- Timothy Blair
- 5 years ago
- Views:
Transcription
1 Page 1 of 12 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE Randomized double-blind controlled trial of roflumilast at acute exacerbations of COPD Authors: Alex J Mackay 1,2 *, Anant RC Patel 2, Richa Singh 1,3, Raymond J Sapsford 3, Gavin C Donaldson 3, Niyati Prasad 4,5, Udo-Michael Goehring 5, Tsz Keung Nip 5, Jadwiga A Wedzicha 3 1 Dept of Respiratory Medicine, The Royal London Hospital, Barts Health NHS Trust, London, UK 2 Centre for Respiratory Medicine, UCL, London, UK 3 Airways Disease Section, National Heart and Lung Institute, Imperial College, London, UK 4 Vertex Pharmaceuticals (Europe) Ltd, London, UK 5 Takeda Development Centre Europe Ltd, London, UK * Corresponding author: ; alexandermackay@nhs.net, telephone; At the time the study was conducted Running title: Roflumilast at acute COPD exacerbation Word count: 1073
2 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE Page 2 of 12 COMPETING INTERESTS Alex Mackay reports grants and non-financial support from Takeda during the conduct of the study, and lecture fees from Takeda and GlaxoSmithKline outside the submitted work. Jadwiga Wedzicha reports board membership fees from GlaxoSmithKline, Novartis, Pfizer, Takeda, Boehringer Ingelheim, Almirall, Johnson and Johnson, Napp, and Vifor Pharma, consultancy fees from Novartis, grants from GlaxoSmithKline, Novartis, Takeda, Johnson and Johnson, and Vifor Pharma, payment for lectures including service on speakers bureaus from Boehringer Ingelheim, GlaxoSmithKline, Takeda, Novartis, AstraZeneca, Almirall, and Chiesi, outside the submitted work. Gavin Donaldson reports personal fees from MiCom SRL, Milan, Italy, outside the submitted work. Richa Singh reports personal lecture fees from Chiesi, outside the submitted work. Tsz Keung Nip is an employee of Takeda Pharmaceuticals. Udo-Michael Goehring and Niyati Prasad were employees of Takeda Pharmaceuticals at the time of the study. Anant Patel and Raymond Sapsford have nothing to disclose. FUNDING All funding for this study was provided by Takeda Pharmaceuticals. AUTHOR CONTRIBUTIONS AJM, GCD, UMG and JAW conceived the idea for the study; data collection and laboratory analysis was undertaken by AJM, ARCP, RS, RJS and data analysis by TKN; all authors contributed to data interpretation and the writing of the paper. KEY WORDS Disease exacerbation, COPD, inflammation, phosphodiesterase 4 inhibitors, roflumilast
3 Page 3 of 12 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE INTRODUCTION Chronic obstructive pulmonary disease (COPD) exacerbations are critical events that lead to poor health status [1], lung function decline [2], and mortality [3]. However, treatment options for acute exacerbations remain limited. Treatment failure with the current standard of care is 27% at 30 days [4] and rises to 37% at 90 days [5]. Thus, new therapies for the management of acute exacerbations are urgently needed. Roflumilast is a phosphodiesterase 4 (PDE4) inhibitor and a non-steroid, anti-inflammatory agent, designed to target both the systemic and pulmonary inflammation associated with COPD. Roflumilast reduces neutrophilic airway inflammation [6], improves lung function and reduces exacerbations in stable COPD patients [7-9], but has not previously been studied as an acute exacerbation therapy. Therefore, we conducted a randomized, double-blind, placebo-controlled study to test the hypothesis that roflumilast reduces neutrophilic inflammation during exacerbations of COPD when added to usual medication. Faster resolution of neutrophilic inflammation is associated with shorter clinical recovery [10]. Thus, this study served as a proof-of-mechanism study to examine whether roflumilast can improve clinical recovery following COPD exacerbations.
4 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE Page 4 of 12 METHODS Treatment with Roflumilast at ExAcerbaTion (TREAT) was a randomized, double-blind, placebo-controlled, parallel-group, single-center, phase II trial. This study was registered with ClinicalTrials.gov (NCT ). Patients were recruited from the London COPD patient cohort if they experienced an acute exacerbation of COPD with bronchitic symptoms (increased sputum volume or change in sputum color) that required additional systemic therapy. Patients requiring hospitalization at exacerbation presentation were not recruited. Patients were randomized at exacerbation presentation to either oral roflumilast 500 µg or placebo, once daily. The double-blind treatment period was 4 weeks followed by a follow-up period of a further 4 weeks. All patients received standardized exacerbation treatment (30 mg prednisolone for 10 days and amoxicillin 500 mg three times per day [clarithromycin/doxycycline in event of penicillin allergy] for 7 days). Clinic visits were performed at Days 1 (exacerbation presentation), 7, 14, 28 and 56 (Figure 1A). The primary endpoint was change in sputum neutrophil counts from Day 1 to Day 14 post exacerbation. Treatment comparison was evaluated using an analysis of covariance model with Day 1 result as covariate and 2-sided significance level of Key secondary endpoints included change in forced expiratory volume in one second (FEV 1 ) and in other sputum inflammatory markers from Day 1 to each post randomization visit, and were evaluated using Mixed Model Repeated Measurement (MMRM) model with baseline value, treatment group, visit, and treatment group-by-visit interaction.
5 Page 5 of 12 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE RESULTS The study included 38 patients randomized to the roflumilast group and 43 patients randomized to the placebo group (Table 1). See Figure 1B for a CONSORT diagram showing the flow of patients. Roflumilast Placebo N=38 N=43 Mean±SD Mean±SD Age (years) 72.9± ±9.3 FEV 1 (L) 1.3± ±0.6 FEV 1 (% predicted) 48.6± ±18.0 FVC (L) 2.7± ±1.0 FEV 1 / FVC ratio (%) 46.7± ±13.3 Smoking pack years 53.1± ±27.1 BMI (kg/m 2 ) 26.8± ±5.8 Exacerbations in year prior to enrolment 1.4± ±1.3 N (%) N (%) Male gender 22 (57.9) 28 (65.1) Current smokers 8 (21.1) 11 (25.6) Chronic bronchitis 24 (63.2) 26 (60.5) Frequent exacerbators ( 2 HCU exacerbations in year prior to enrolment) 10 (26.3) 15 (34.9) Table 1. Baseline clinical characteristics. Stable state clinical characteristics of patients included. FEV 1 = forced expiratory volume in one second; FVC=forced vital capacity; BMI=body mass index; HCU=health care utilization; SD=standard deviation.
6 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE Page 6 of 12 Primary outcome: change in sputum neutrophil count from Day 1 (exacerbation presentation) to Day 14. There was no significant difference in change in absolute sputum neutrophil count (10 6 cells/g sputum) from Day 1 to Day 14 between the roflumilast group and the placebo group (Figure 1C). Least squares (LS) mean change in sputum neutrophil count from Day 1 to Day 14 for roflumilast was (95% confidence interval (CI) -23.2, -14.2) and for placebo was (95% CI -24.1, -16.1); the between treatment difference did not reach statistical significance (1.4 [95% CI -4.7, 7.5]; p=0.649). Secondary outcomes: lung function Compared with placebo, change in FEV 1 from Day 1 was numerically greater in the roflumilast-treated group at Day 7 and at Day 14 by approximately 50 ml, although this did not meet the threshold for statistical significance. At the end of treatment at Day 28, there was a non-statistically significant greater increase in FEV 1 in the roflumilast group by 94 ml (95% CI -2, 191; p=0.055) (Figure 1D). Secondary outcomes: airway inflammation Compared with placebo, roflumilast use significantly reduced airway inflammation as shown by change from Day 1 to Day 28 in % sputum neutrophils (-13.9% [95% CI -27.8, -0.09]; p=0.049), and sputum myeloperoxidase (MPO) concentration ( ng/ml [95% CI , ]; p=0.018).
7 Page 7 of 12 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE Adverse events Adverse events (AEs) with suggested relationship to the investigational medicinal product were reported in 33 (86.8%) and 16 (37.2%) patients in the roflumilast and placebo groups respectively; serious AEs were reported by 4 (10.5%) patients and 1 (2.3%) patient in the roflumilast and placebo groups respectively. The most frequently reported AEs were diarrhea (reported in 25 [65.8%] and 10 [23.3%] patients in roflumilast and placebo groups respectively), COPD exacerbations (reported in 17 [44.7%] and 14 [32.6%] patients in roflumilast and placebo groups respectively), and insomnia (reported in 12 [31.6%] and 2 [4.7%] patients in roflumilast and placebo groups respectively). Events led to withdrawal from the study in 10 (26.3%) patients in the roflumilast group compared with 2 (4.7%) patients in the placebo group. No deaths occurred over the entire course of the study. Weight assessment Between Day 1 and Day 28, patients in the roflumilast group lost 2.0 kg (SD: 1.6) in body weight; whilst in the placebo group, patients gained 0.1 kg (SD: 0.9).
8 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE Page 8 of 12 DISCUSSION Roflumilast, when given in addition to standard therapy, did not accelerate reduction of sputum neutrophils from exacerbation onset to 2 weeks post exacerbation, which was the study s primary outcome. However in exploratory analyses, at 4 weeks, patients treated with roflumilast experienced a statistically significant greater reduction in percentage sputum neutrophils and sputum MPO concentration. Moreover, roflumilast use led to trends in benefits in lung function. Patients treated with roflumilast had over 40 ml improvement at 1 week, over 50 ml improvement at 2 weeks, and almost 100 ml additional improvement in FEV 1 at 4 weeks, compared with patients treated with antibiotics and steroids alone. However, these differences were not statistically significant. AEs and withdrawal rates in this study were higher in the roflumilast group. Additionally, 2.0 kg weight loss over 28 days in the roflumilast group is concerning, as it is similar to that seen over a year in studies of patients in the stable state [7, 9]. Further studies would be required to confirm the positive effects on lung function recovery seen in this study, and accurately define the optimum use of roflumilast as an acute exacerbation treatment. This study suggests days post exacerbation may be the most advantageous time to administer roflumilast as this is when improved outcomes are observed. However, the high AE rates seen in this study may limit the tolerability and applicability of roflumilast in clinical practice in the acute setting.
9 Page 9 of 12 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE ACKNOWLEDGEMENTS Editorial assistance provided by Alexis Pashiardis, Synergy Vision (London, UK), was funded by Takeda and AstraZeneca.
10 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE Page 10 of 12 REFERENCE LIST 1. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 1998;157: Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57: Soler-Cataluna JJ, Martinez-Garcia MÁ, Sánchez PR, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60: Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;348: Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340: Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, Bethke TD, Hiemstra PS, Rabe KF. Reduction in sputum neutrophil and eosinophil
11 Page 11 of 12 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62: Calverley PMA, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374: Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, Bundschuh D, Brose M, Martinez FJ, Rabe KF. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374: Martinez FJ, Calverley PMA, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015;385: Perera WR, Hurst JR, Wilkinson TMA, Sapsford RJ, Mullerova H, Donaldson GC, Wedzicha JA. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007;29:
12 AJRCCM Articles in Press. Published on 01-February-2017 as /rccm LE Page 12 of 12 FIGURE LEGENDS Figure 1A. Clinical trial design. od=once daily. Figure 1B. Study profile. Enrolment did not reach the original intended power calculation (140 patients) because recruitment was curtailed early by the scientific oversight committee. Figure 1C. Change in sputum neutrophil count from Day 1 14 (10 6 cells/g sputum). Lines represent 95% lower confidence intervals. Figure 1D. Change in FEV 1 from exacerbation presentation. Data are least squares means ± standard error in the intention-to-treat population. Least squares means are from the MMRM. Covariates for MMRM are baseline value, treatment, visit, and treatment by visit interaction. Covariance structure = unstructured. LS=least squares. FEV 1 = forced expiratory volume in one second. MMRM=mixed model repeated measurement.
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationTo describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype.
Educational aims To describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype. To describe the spectrum of pharmacological and non-pharmacological interventions
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationRoflumilast: Οι κλινικές μελέτες
Roflumilast: Οι κλινικές μελέτες Επαμεινώνδας Ν. Κοσμάς Δ/ντής Πνευμονολογικού Τμήματος Νοσοκομείου Metropolitan PDE4 PLAYS AN IMPORTANT ROLE IN INFLAMMATION PDE4 inhibition P P P PDE4 P Adapted from Rabe
More informationCOPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK
COPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK Presenter Disclosures Wisia Wedzicha All disclosures prior
More informationRoflumilast for the treatment of respiratory disease: review of the Phase II and III trials
Roflumilast for the treatment of respiratory disease: review of the Phase II and trials Clin. Invest. (2011) 1(10), 1413 1419 Roflumilast (Daxas [EU], Daliresp [USA]) is the first phospho diesterase 4
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationRoflumilast with long-acting b 2 -agonists for COPD: influence of exacerbation history
Eur Respir J 211; 3: 553 56 DOI: 1.113/9319.1771 CopyrightßERS 211 with long-acting b 2 -agonists for COPD: influence of exacerbation history E.D. Bateman*, K.F. Rabe #,", P.M.A. Calverley +, U.M. Goehring
More informationFrancesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy
COPD EXACERBATIONS Francesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy COPD OUTCOMES Cazzola M et al. ERJ 2008 COPD AND CARDIOVASCULAR DISEASE Cumulative
More informationRe-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September
Re-Submission roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd 4 August 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationFernando J Martinez*, Peter M A Calverley*, Udo-Michael Goehring, Manja Brose, Leonardo M Fabbri, Klaus F Rabe
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial Fernando J Martinez*,
More informationTime course and pattern of COPD exacerbation onset
< An additional material is published online only. To view this file please visit the journal online (http://thorax.bmj.com/ content/67/3.toc). 1 Department of Medicine, The Ottawa Hospital Research Institute,
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationC hronic obstructive pulmonary disease (COPD) is one of
589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See
More informationReport of the COPD7 Conference Conference Report Sponsored by
Report of the COPD7 Conference 2010 Conference Report Sponsored by Report of the COPD7 Conference 2010 CONTENTS Burden of COPD Pages 3-4 Current challenges in COPD management Pages 5-6 Overcoming challenges
More informationStatistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited
Eur Respir J 28; 32: 17 24 DOI: 1.1183/931936.16157 CopyrightßERS Journals Ltd 28 PERSPECTIVE Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited O.N. Keene*, P.M.A. Calverley
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationJournal of the COPD Foundation
132 Predictors of Change in SGRQ Score Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Original Research Baseline Severity as Predictor of Change in St George s Respiratory Questionnaire
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationChronic Obstructive Pulmonary Diseases:
74 Roflumilast Effect on COPD Rehospitalization Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Original Research Effects of Roflumilast on Rehospitalization and Mortality in Patients
More informationResearch Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD
Research Review Salmeterol/fluticasone propionate (Seretide ) in COPD Extended listing for salmeterol/fluticasone propionate in COPD In New Zealand, salmeterol/fluticasone propionate (SFC) (Seretide )
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationAcute exacerbations of chronic obstructive
Eur Respir Rev 2005; 14: 95, 78 82 DOI: 10.1183/09059180.05.00009507 CopyrightßERSJ Ltd 2005 Modulation of airway inflammation to prevent exacerbations of COPD M. Solèr ABSTRACT: Exacerbations of chronic
More informationDr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective
Dr Stephen Child General Physician Auckland 14:20-14:40 Secondary Care Perspective Wheeze Witchery Stephen Child MD, FRACP, FRCPC General Physician Respiratory Interest Director of Clinical Training Auckland
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationABNORMAL RECOVERY CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS AND RECURRENCE OF. Alexander John Mackay BSc MRCP
ABNORMAL RECOVERY AND RECURRENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS Alexander John Mackay BSc MRCP A thesis submitted for the degree of Doctor of Philosophy, 2016 Centre for Respiratory
More informationCOPD Bronchiectasis Overlap Syndrome.
COPD Bronchiectasis Overlap Syndrome. John R Hurst 1, J Stuart Elborn 2, and Anthony De Soyza 3 on Behalf of the BRONCH-UK Consortium (D Bilton, J Bradley, JS Brown, J Duckers, F Copeland, A Floto, J Foweraker,
More informationEffect of tiotropium on sputum and serum inflammatory markers and. exacerbations in chronic obstructive pulmonary disease
ERJ Express. Published on May 15, 2007 as doi: 10.1183/09031936.00023907 Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in chronic obstructive pulmonary disease Duncan
More informationCOPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI
COPD: From Phenotypes to Endotypes MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI Presenter Disclosures MeiLan K. Han Consulting Research support Novartis
More informationJournal Club: COPD and Rehospitalization Ron Balkissoon, MD, MSc, DIH, FRCPC 1
791 Journal Club: Rehospitalization Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club: COPD and Rehospitalization Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations:
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationT he prevalence of chronic obstructive pulmonary
164 REVIEW SERIES COPD exacerbations? 1: Epidemiology G C Donaldson, J A Wedzicha... The epidemiology of exacerbations of chronic obstructive pulmonary disease (COPD) is reviewed with particular reference
More informationSGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life
SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationShaping a Dynamic Future in Respiratory Practice. #DFResp
Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory
More informationOptimum treatment for chronic obstructive pulmonary disease exacerbation prevention
Commentary Page 1 of 5 Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention Pradeep Karur, Dave Singh Centre for Respiratory Medicine and Allergy, Medicines Evaluation Unit,
More informationCirculating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study
ORIGINAL ARTICLE COPD Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study Yochai Adir 1, Omar Hakrush 1, Michal Shteinberg 1, Sonia Schneer 1 and Alvar Agusti
More informationBrand Name: Daliresp. Generic Name: roflumilast. Manufacturer: Forest Pharmaceuticals, Inc.
Brand Name: Daliresp Generic Name: roflumilast 3, 4, 5 Manufacturer: Forest Pharmaceuticals, Inc. 1, 2,4,5,7 Drug Class: Second Generation Phosphodiesterase 4 (PDE 4) inhibitor Labeled Uses: prophylaxis
More informationProductivity losses in chronic obstructive pulmonary disease a population-based survey.
Online supplement to Productivity losses in chronic obstructive pulmonary disease a population-based survey. Running head: Productivity losses in COPD. Authors: Marta Erdal, Department of Thoracic Medicine,
More informationControversies in Clinical Trials
Controversies in Clinical Trials Christopher B Cooper, MD Professor of Medicine and Physiology David Geffen School of Medicine Medical Director, UCLA COPD Center Methodological issues discussed Pitfalls
More informationA controlled trial of 6 weeks treatment with a novel inhaled
ERJ Express. Published on February 12, 2009 as doi: 10.1183/09031936.00068908 A controlled trial of 6 weeks treatment with a novel inhaled PDE 4 inhibitor in COPD Jørgen Vestbo 1,2, Lisa Tan 3, Gary Atkinson
More informationChronic obstructive pulmonary disease (COPD) is characterized
RESEARCH Impact of COPD Exacerbation Frequency on Costs for a Managed Care Population Anand A. Dalal, PhD, MBA; Jeetvan Patel, MS; Anna D Souza, BPharm, PhD; Eileen Farrelly, MPH; Saurabh Nagar, MS; and
More informationOutpatient Oral Prednisone after Emergency Treatment of Chronic Obstructive Pulmonary Disease
The new england journal of medicine original article Outpatient Oral Prednisone after Emergency Treatment of Chronic Obstructive Pulmonary Disease Shawn D. Aaron, M.D., Katherine L. Vandemheen, B.Sc.N.,
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationDisclosures. Update on COPD & Asthma. Update on the Management of COPD. No Pharma Disclosures. NHLBI - Asthma Clinical Research Network
Update on COPD & Asthma Michael C. Peters, M.D. MAS Division of Pulmonary & Critical Care Medicine Cardiovascular Research Institute University of California San Francisco UCSF Primary Care Medicine San
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationThe Journal Club: COPD Exacerbations
252 The Journal Club: COPD Exacerbations Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club The Journal Club: COPD Exacerbations Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations:
More informationPrevention of COPD exacerbations: medications and other controversies
REVIEW COPD Prevention of COPD exacerbations: medications and other controversies Jørgen Vestbo 1 and Peter Lange 2,3 Affiliations: 1 Centre for Respiratory Medicine and Allergy, Institute of Inflammation
More informationChanging Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?
New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationStudy Investigators/Centers: GSK sponsored studies MEA112997, MEA115588, and MEA and a proof of concept investigator sponsored study CRT110184
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTwo cases of COPD benefitting from therapy with roflumilast
Monaldi Arch Chest Dis 2013; 79: 3-4, Suppl., 23-28 CASE REPORT Two cases of COPD benefitting from therapy with roflumilast Chiara Francesca Carraro 1* ABSTRACT: Two cases of COPD benefitting from therapy
More informationCharacterisation and impact of reported and unreported exacerbations: results from ATTAIN
ORIGINAL ARTICLE COPD Characterisation and impact of reported and unreported exacerbations: results from ATTAIN Paul W. Jones 1, Rosa Lamarca 2, Ferran Chuecos 2, Dave Singh 3, Alvar Agustí 4,5, Eric D.
More informationAbbreviated Class Review: Chronic Obstructive Pulmonary Disease (COPD)
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Executive summary: Month/Year of Review: February
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationSpirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial
Watz et al. Respiratory Research (2018) 19:251 https://doi.org/10.1186/s12931-018-0944-3 RESEARCH Open Access Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial Henrik
More information#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA
Where There s Smoke There s Obstruction Stephen G. Basheda, D.O., F.C.C.P. 1 Disclosures Dr. Basheda is an independent contractor for AstraZeneca Pharmaceuticals, LP and GlaxoSmithKline and on the speaker
More informationReport of the American Thoracic Society International Conference 2010 Conference Report Sponsored by
Report of the American Thoracic Society International Conference 2010 Conference Report Sponsored by 1 Report of the American Thoracic Society International Conference 2010 CONTENTS What should we treat?
More informationTitle: Objective measurement of cough frequency during COPD exacerbation convalescence
The final publication is available at Springer via http://dx.doi.org/10.1007/s00408-015-9782-y Title: Objective measurement of cough frequency during COPD exacerbation convalescence Michael G Crooks 1,
More informationClinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study
ORIGINAL ARTICLE COPD Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study Masaru Suzuki 1, Hironi Makita 1, Yoichi M. Ito 2, Katsura Nagai 1, Satoshi Konno 1 and Masaharu
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationPhysiological Effects of Roflumilast at Rest and during Exercise in COPD
ERJ Express. Published on September 29, 2011 as doi: 10.1183/09031936.00096511 Physiological Effects of Roflumilast at Rest and during Exercise in COPD Authors: Denis E. O Donnell 1, MD; Dirk Bredenbröker
More informationDetrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD
Eur Respir J 2012; 40: 1123 1129 DOI: 10.1183/09031936.00180811 CopyrightßERS 2012 Detrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD Gavin C. Donaldson*, Terence
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationAn Update in COPD John Hurst PhD FRCP
An Update in COPD John Hurst PhD FRCP Reader in Respiratory Medicine / Honorary Consultant University College London / Royal Free London NHS Foundation Trust j.hurst@ucl.ac.uk What s new in COPD papers
More informationRE: NICE STA of Roflumilast for the Management of Chronic Obstructive Pulmonary Disease Response to the Appraisal Consultation Document
MSD Hertford Road Hoddesdon Hertfordshire EN11 9BU UK Telephone +44 (0)1992 452644 Facsimile +44 (0)1992 468175 National Institute for Health and Clinical Excellence MidCity Place 71 High Holborn London
More informationC.S. HAWORTH 1, A. WANNER 2, J. FROEHLICH 3, T. O'NEAL 3, A. DAVIS 4, I. GONDA 3, A. O'DONNELL 5
Inhaled Liposomal Ciprofloxacin in Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa: Results From Two Parallel Phase III Trials (ORBIT-3 and -4) C.S. HAWORTH 1, A. WANNER
More informationDisease progression in COPD:
Disease progression in COPD: What is it? How should it be measured? Can it be modified? Professor Paul Jones MD, PhD, FERS Emeritus Professor of Respiratory Medicine; St George s, University of London
More informationThe Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia.
The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. Rennard, Stephen I; Sin, Donald D; Tashkin, Donald P; Calverley, Peter M; Radner, Finn Published in: Annals
More informationBronchial Provocation Results: What Does It Mean?
Bronchial Provocation Results: What Does It Mean? Greg King 1 Department of Respiratory Medicine, Royal North Shore Hospital, St Leonards 2065 2 Woolcock Institute of Medical Research and Sydney Medical
More informationBlood eosinophil count: a biomarker of an important treatable trait in patients with airway disease
EDITORIAL COPD Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease Ian D. Pavord 1 and Alvar Agusti 2 Affiliations: 1 Respiratory Medicine Unit, Nuffield
More informationReduced lung function in midlife and cognitive impairment in the elderly
Page 1 of 5 Reduced lung function in midlife and cognitive impairment in the elderly Giuseppe Verlato, M.D. Ph.D Department of Diagnostics and Public Health University of Verona Verona, Italy Mario Olivieri,
More informationLong-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality
1 Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada 2 Department of Epidemiology and Biostatistics, and Department of Medicine, McGill University, Montreal,
More informationH ospitalisation due to an exacerbation of chronic
713 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationWeek 23 Respirology. Other Asthma & COPD Medications Self Learning Module
Week 23 Respirology Other Asthma & COPD Medications Self Learning Module DISCLOSURE Relevant relationships with commercial entities [None] Potential for conflicts of interest within this presentation [None]
More informationFactors associated with change in exacerbation frequency in COPD
Donaldson et al. Respiratory Research 2013, 14:79 RESEARCH Open Access Factors associated with change in exacerbation frequency in COPD Gavin C Donaldson 1*, Hanna Müllerova 2, Nicholas Locantore 3, John
More informationThe role of bronchodilator treatment in the prevention of
ERJ Express. Published on July 26, 2012 as doi: 10.1183/09031936.00048912 The role of bronchodilator treatment in the prevention of exacerbations of COPD JA Wedzicha*, M Decramer #, TAR Seemungal *Professor
More informationSenior Medicine Rotation: Evidence-Based Medicine Project. Student Name: Elizabeth Heuzey Block: November 2011 Date: 11/29/2011
C OLUMBIA U NIVERSITY M EDICAL C ENTER D IVISION OF G ENERAL M EDICINE Senior Medicine Rotation: Evidence-Based Medicine Project Student Name: Elizabeth Heuzey Block: November 2011 Date: 11/29/2011 Case
More informationCommunity COPD Service Protocol
Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults
More informationConfronting the Challenges of COPD. What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes
Confronting the Challenges of COPD What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes COPD Definition GOLD: Global Initiative for Chronic Obstructive Lung Disease Common, preventable,
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationProf Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
More informationOral corticosteroids for exacerbations of chronic obstructive pulmonary disease
Thorax 2000;55(Suppl 1):S23 S27 S23 Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease J A Wedzicha Academic Respiratory Medicine, St Bartholomew s and Royal London School
More informationSelf-management reduces both short- and long-term hospitalisation in COPD
Eur Respir J 2005; 26: 853 857 DOI: 10.1183/09031936.05.00093204 CopyrightßERS Journals Ltd 2005 Self-management reduces both short- and long-term hospitalisation in COPD M-A. Gadoury*, K. Schwartzman*,
More informationJournal Club: Phosphodiesterase-4 Inhibitors Ron Balkissoon, MD, MSc, DIH, FRCPC 1
693 Journal Club: Phosphodiesterase-4 Inhibitors Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club: Phosphodiesterase-4 Inhibitors Ron Balkissoon, MD, MSc, DIH, FRCPC
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More information